Abstract
The cancer originated from large bowel represents a widespread cancer along the world and a considerable percentage of new cases are diagnosed with distant disease. Recently, the detection of “clever” medicaments such as focused therapy was the outcome of an improved comprehension of the procedures that transform physiological tissues to tumor. The family of focused medication includes medicaments that specifically affect specific molecular routes implicated in the production of the tumor and its development. The new natural substances aim at inhibiting the procedure of angiogenesis which is fundamental for cancer development and distant metastasis. This process of angiogenesis and tumor development is inhibited by Bevacizumab a humanized recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding. The usage of bevacizumab as primary therapy for patients with metastatic colorectal cancer was approved by FDA (Food and Drug Administration) on February 26, 2004. Incorporating the focused therapies in the management of metastatic colon cancer has led to considerable advance in efficiency results. In this review article, the effectiveness of bevacizumab given as primary therapy in patients with large bowel tumor and distant metastases is analysed.
Keywords: Avastin, bevacizumab, metastatic colorectal cancer.
Current Cancer Therapy Reviews
Title:Primary Management of Metastatic Colorectal Cancer with Bevacizumab. Review Article Focusing on Efficacy
Volume: 11 Issue: 2
Author(s): Georgios Koukourakis, Georgios Zacharias and Aristides Petridis
Affiliation:
Keywords: Avastin, bevacizumab, metastatic colorectal cancer.
Abstract: The cancer originated from large bowel represents a widespread cancer along the world and a considerable percentage of new cases are diagnosed with distant disease. Recently, the detection of “clever” medicaments such as focused therapy was the outcome of an improved comprehension of the procedures that transform physiological tissues to tumor. The family of focused medication includes medicaments that specifically affect specific molecular routes implicated in the production of the tumor and its development. The new natural substances aim at inhibiting the procedure of angiogenesis which is fundamental for cancer development and distant metastasis. This process of angiogenesis and tumor development is inhibited by Bevacizumab a humanized recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding. The usage of bevacizumab as primary therapy for patients with metastatic colorectal cancer was approved by FDA (Food and Drug Administration) on February 26, 2004. Incorporating the focused therapies in the management of metastatic colon cancer has led to considerable advance in efficiency results. In this review article, the effectiveness of bevacizumab given as primary therapy in patients with large bowel tumor and distant metastases is analysed.
Export Options
About this article
Cite this article as:
Koukourakis Georgios, Zacharias Georgios and Petridis Aristides, Primary Management of Metastatic Colorectal Cancer with Bevacizumab. Review Article Focusing on Efficacy, Current Cancer Therapy Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573394711666151022203012
DOI https://dx.doi.org/10.2174/1573394711666151022203012 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges
Current Medicinal Chemistry Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management
Current Drug Metabolism Wnt Signaling in Rhabdomyosarcoma – A Potential Targeted Therapy Option
Current Drug Targets Legumes: A Healthy and Ecological Source of Flavonoids
Current Nutrition & Food Science Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development
Current Molecular Medicine Tissue-Specific Therapeutic Targeting of p53 in Cancer: One Size Does Not Fit All
Current Pharmaceutical Design Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Himalayan Plants as a Source of Anti-Cancer Agents: A Review
The Natural Products Journal Identification of Multiple Subcellular Locations for Proteins in Budding Yeast
Current Bioinformatics LncRNAs as Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy
Current Cancer Drug Targets TGFb and its Smad Connection to Cancer
Current Genomics Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Unveiling Cancer in IBD: Screening Colonoscopy or Chromoendoscopy
Current Drug Targets Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Micelles As Delivery System for Cancer Treatment
Current Pharmaceutical Design Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Current Molecular Medicine